Buoyed by the recent launch of Stelo and further upcoming CGM launches, Dexcom is anticipating a 14% growth in 2025 over 2024.

Continuous glucose monitors like Dexcom's Stelo and Abbott's Lingo are small, wearable devices that track blood glucose ...

Fifth Third Bancorp grew its holdings in shares of DexCom, Inc. (NASDAQ:DXCM – Free Report) by 21.5% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm ...

DexCom's stock is fairly valued despite positive Q4 2024 results, with muted enthusiasm from Wall Street today. Click here to ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $95.91, ...

DXCM's top line reflects strong demand for its CGM sensors. International expansion is also driving sales higher. Gross margin reflects inventory damage.

Notably, Dexcom continues to innovate, with a future iteration of its CGM on the way. Sayer described the next-generation ...

The S&P 500 slid 0.2% on Thursday, Jan. 16, 2025, losing momentum after posting solid gains driven by earnings and inflation ...

DexCom Inc. closed 43.38% below its 52-week high of $142.00, which the company reached on March 26th.

On Friday, DexCom Inc (DXCM) stock saw a decline, ending the day at $84.38 which represents a decrease of $-0.46 or -0.54% from the prior close of $84.84. The stock opened at $86.32 and touched a low ...

After spending the past year extending its portfolio of continuous glucose monitors to include people who may not have diabetes, Dexcom said it expects to see more than $4.0 | The blood sugar tracking ...

Dexcom (DXCM – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on January 13. Analyst Mike Kratky from ...